Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

被引：87
|
作者：
Hamilton, Chad A. [1 ]
Maxwell, G. Larry [1 ]
Chemofsky, Mildred R. [1 ]
Bernstein, Sarah A. [1 ]
Farley, John H. [1 ]
Rose, G. Scott [1 ]
机构：
[1] Walter Reed Army Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Washington, DC 20307 USA
来源：
GYNECOLOGIC ONCOLOGY | 2008年 / 111卷 / 03期
关键词：
Bevacizumab; Intraperitoneal; Ovarian cancer; Ascites; Palliation;
D O I：
10.1016/j.ygyno.2008.04.028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background. Malignant ascites often has a profound impact on the quality of life of patients with refractory ovarian cancer. Current treatments, including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. Case. We present a case of an 88 year-old receiving home hospice care with refractory ovarian cancer and severe symptomatic ascites. We performed a paracentesis and treated her with intraperitoneal bevacizumab with dramatic improvement in her ascites and the quality of her final weeks of life. Conclusion. Intraperitoneal bevacizumab may be a useful 1001 in the palliation of malignant ascites and is worthy of further study. Published by Elsevier Inc.
引用
收藏
页码：530 / 532
页数：3
相关论文
共 50 条
  • [31] Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?
    Kobold, Sebastian
    Hegewisch-Becker, Susanna
    Oechsle, Karin
    Jordan, Karin
    Bokemeyer, Carsten
    Atanackovic, Djordje
    ONCOLOGIST, 2009, 14 (12): : 1242 - 1251
  • [32] PERITONEOVENOUS SHUNT FOR PALLIATION OF MALIGNANT ASCITES
    QAZI, R
    SAVLOV, ED
    CANCER, 1982, 49 (03) : 600 - 602
  • [33] Different sequential approaches of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites
    Ba, Mingchen
    Long, Hui
    Zhang, Xiangliang
    Tang, Yunqiang
    Wu, Yinbing
    Yu, Feihong
    Wang, Shuai
    Cui, Shuzhong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (09) : 1497 - 1506
  • [34] PALLIATION OF MALIGNANT ASCITES WITH A TENCKHOFF CATHETER
    LOMAS, DA
    WALLIS, PJW
    STOCKLEY, RA
    THORAX, 1989, 44 (10) : 828 - 828
  • [35] Different sequential approaches of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites
    Mingchen Ba
    Hui Long
    Xiangliang Zhang
    Yunqiang Tang
    Yinbing Wu
    Feihong Yu
    Shuai Wang
    Shuzhong Cui
    Journal of Cancer Research and Clinical Oncology, 2014, 140 : 1497 - 1506
  • [36] INTRAPERITONEAL INFUSION OF RECOMBINANT INTERLEUKIN-2 IN MALIGNANT ASCITES IN PATIENTS WITH GASTROINTESTINAL AND OVARIAN-CANCER
    BERTOGLIO, S
    MELIOLI, G
    BALDINI, E
    CATTURICH, A
    SERTOLI, MR
    CIVALLERI, D
    PERCIVALE, P
    MEIER, W
    GALAZKA, A
    BADELLINO, F
    ACTA MEDICA AUSTRIACA, 1989, 16 (3-4) : 81 - 83
  • [37] The usefulness of bevacizumab for relief from symptomatic malignant ascites in patients with heavily treated recurrent ovarian cancer
    Shimizu, Yusuke
    Kajiyama, Hiroaki
    Yoshida, Kosuke
    Tamauchi, Satoshi
    Nakanishi, Toru
    Kikkawa, Fumitaka
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2019, 45 (12) : 2435 - 2439
  • [38] Intraperitoneal Recombinant Human Endostatin Combined with Chemotherapy for Refractory Malignant Ascites due to Gastrointestinal Cancer: A Pilot Study
    Xue, Sheng Liu
    Deng, Xia
    Liu, Yang
    Su, Hua Fang
    Hu, Mei Long
    Xie, Cong Ying
    HEPATO-GASTROENTEROLOGY, 2013, 60 (121) : 118 - 123
  • [39] Effective palliation of refractory ascites in cirrhosis is challenging
    Abbott, Jane
    Verma, Sumita
    Saksena, Sushma
    INTERNATIONAL JOURNAL OF PALLIATIVE NURSING, 2024, 30 (06) : 286 - 293
  • [40] INTRAPERITONEAL INTERFERON IN THE MANAGEMENT OF MALIGNANT ASCITES
    STUART, GCE
    NATION, JG
    SNIDER, DD
    THUNBERG, P
    CANCER, 1993, 71 (06) : 2027 - 2030
12345